

leading innovation
in medical imaging

eigen



Virtual MRI Guided Prostate Biopsy

MRI/Ultrasound Fusion Technology

3D Semi-Robotic Targeting

www.eigen.com

leading innovation
in medical imaging



Advanced 3D Imaging

3D DICOM Visualization

PACS Compliant




Prostate & ROI Contouring

Perfusion-Diffusion Analysis

Data Transfer via USB, DVD, Network or Cloud

Image Histogram Analysis

Easy & Efficient Workflow




*Integration of pathology results into MRI for review
and treatment planning, e.g. Focal Therapy*

ProFuse™


leading innovation
in medical imaging





ProFuse is a powerful mpMRI DICOM viewer that enables radiologists, urologists or radiation oncologists to identify and confirm potential prostate MR lesions for biopsy. It writes and reads from PACS. It is easily configured to user's choice. It allows advanced calculation to confirm lesion grading. Setup is quick and easy with remote license activation. The end-user receives 3-user licenses as part of the bundle platform. This allows multiple locations to read mpMRI and mark regions of interest for biopsy procedures. Training on the software is easy and provided on-site.




mpMRI Visualization




Perfusion/Diffusion Analysis



Prostate and ROI Contouring



mpMRI Histogram Analysis




PIRADS Reporting

ProFuse™


leading innovation
in medical imaging




Multi-Modality Image Fusion



Supports PET/CT/MRI/US Fusion
Automatic Rigid & Elastic Fusion
With or Without Endorectal Coil
All MR Scanners & Protocols
PIRADS Reporting & Scoring
Accounts for Bladder/Rectal Filling



MRI



Ultrasound

Integrate information from mpMRI into TRUS guided biopsy



ProFuse BxTM

leading innovation
in medical imaging

eigen

Precision Targeting

Eliminates prostate deformation for high accuracy of targeted biopsy



Targeted MR/Ultrasound Biopsy

Patient Motion Compensation

Custom Template Biopsy Plans

Compatible with all U/S systems

Easy Calibration

Targeted mpUltrasound Bx

Electromechanical Probe Stabilization

3D Needle Visualization & Pathology Recording

3D Semi Robotic Navigation for Prospective Targeting

Detailed Reporting including Previous Biopsy Cores


ArtemisTM

leading innovation
in medical imaging




precisely target suspected lesions in a repeatable manner

Scan




Plan




Fuse



Biopsy



Report



Artemis lets your physician examine, map, plan and record your biopsy. Its 3D detail lets you see the precise location of suspicious tissue and/or cancer lesions. This results in advanced clinical information to aid in your diagnosis, treatment and continuing patient care.

ArtemisTM

Benefits

Clinical

- Avoid *freehand biopsy* errors
- Early detection of malignant tumors
- Easy guidance to target anterior lesions
- Active surveillance & focal therapy
- Reduce repeat biopsy sessions

Operational

- Quick set-up & intuitive workflow
- No sensor-based needle supplies
- No specialized room
- PACS, cloud & network connectivity
- Compatible with all MRI and U/S systems
- Seamless radiology-urology integration

Financial

- Reduce unnecessary biopsy costs
- Reduce unnecessary supply costs
- Cost benefits of early detection of PCa
- Increased patient satisfaction & retention

Clinical PCa Detection Rate

Conventional U/S

Blind *Poke & Hope* Procedure

Detection Rate: 27-40%

False Negative Rate ~47%

38% Repeat Biopsy within 5 Years

Often Anterior Lesions Missed

(Patel AR et al. Curr Opin Urol 2009; 19:232)

mpMRI

Combine Anatomical & Functional Imaging


Comparison of 3 Protocols in 83 Patients

Protocol	Sensitivity	Specificity	Accuracy	AUC
T2W	73%	54%	64%	0.711
T2W + DWI	84%	85%	84%	0.905
T2W + DWI + DCE	95%	74%	86%	0.966

(Tanimoto A, JMRJ 2007)

Multiparametric MRI has excellent sensitivity for detecting aggressive PCa Gleason score 7 or higher

Commitment to Evidence-Based Medicine



# Patients	19	14	61	61	16
# Any CaP	6	6	29	34	15
# Gleason ≥ 7 CaP	3	1	9	14	7

94% of men with image grade 5 on MRI had PCa


J Urol. 2013 Jan; 189(1): 86–91.

Accurate targeting of lesions identified on mpMRI using ultrasound fusion biopsy in clinic


Workflow




mpMRI



PACS Connectivity




Reading and Target planning



Data Transfer



Profuse™



Ultrasound







Image Fusion



Biopsy Planning



Precision Guidance & Recording



Reporting & Documentation



Profuse BX™

Artemis™

leading innovation
in medical imaging

eigen

eigen brings innovation to prostate biopsy & focal therapy



FDA, CE, TGA, CMDCAS Certified

World-class customer support and service

For more information please contact

U.S. Headquarters:
13366 Grass Valley Ave.
Grass Valley, CA 95945
U.S.A.

www.eigen.com

Europe Office:
Denshaw House,
120/121 Lower Baggot St.
Dublin, 2
DO2 FD4

Ph: + 1 530 274 1240 x 221

Fax: + 1 530 274 3656

info@eigen.com